 Curis, Inc. NASDAQ: CRIS shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myeloid leukemia and myelodysplastic syndromes. What Happened: As of Nov. 23, four AML and three high-risk MDS patients were enrolled in the first two study cohorts of the Phase 1 study that evaluated CA-4948, a small-molecule IRAK4 kinase inhibitor, the company said, citing preliminary data. 